Hangzhou Taikun Equity Investment Fund

Hangzhou Taikun Equity Investment Fund is a specialized healthcare-focused investment vehicle established through a partnership between Hangzhou Tigermed Consulting and the Hangzhou government. With a target size of approximately 20 billion RMB, the fund focuses on strategic investments across the entire life sciences value chain, including innovative drug development, medical devices, and healthcare services. It leverages Tigermed's extensive clinical research resources to identify and support high-growth biotech companies both within China and internationally. The fund serves as a critical pillar in Hangzhou's regional strategy to build a world-class biopharmaceutical industrial cluster.